AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Feb 5, 2021
31289_dirs_2021-02-05_6f3d9a8f-a41f-470e-83d3-edfd734ad4f3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-03
Reporting Person: Berkman Charles S (SVP, Gen. Counsel & Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-03 | Common Stock | A | 3491 | $0.0 | Acquired | 47003 | Direct |
| 2021-02-04 | Common Stock | S | 18097 | $178.5034 | Disposed | 28906 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | Employee Stock Option (right to buy) | $177.5 | A | 6955 | Acquired | 2021-02-03 | Common Stock (6955) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.33 to $179.90, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021.